Abogen Biosciences Co., Ltd. (“Abogen”), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance RNA‑encoded therapeutics. The transaction grants Novartis an exclusive worldwide license to Abogen’s lead asset ABO2203, an mRNA‑encoded CD19xCD3 T‑cell engager, together with exclusive options to license additional programs built on Abogen’s proprietary RNA platform.
Deal Snapshot
| Item | Detail |
|---|---|
| Licensor | Abogen Biosciences Co., Ltd. – clinical‑stage mRNA biotechnology group |
| Licensee | Novartis AG (NYSE: NVS) |
| Deal Type | Exclusive worldwide license + multi‑program platform options |
| Lead Asset | ABO2203 – mRNA‑encoded CD19xCD3 T‑cell engager |
| Upfront Payment | USD 575 million |
| Potential Milestones | Up to approximately USD 7.2 billion if all options on all programs are exercised |
| Royalties | Potential royalties on future product sales |
| Options | Exclusive options to license next‑generation therapeutic assets from Abogen’s RNA platform |
| Conditions | Customary closing conditions, including required regulatory clearances |
| Announcement Date | 2 Oct 2026 |
Drug Profile & Mechanism of Action
- Molecule: ABO2203 – a novel mRNA‑encoded CD19xCD3 T‑cell engager with the potential to transform the treatment landscape for patients with autoimmune diseases.
- Targets: CD19 (B‑cell surface antigen) × CD3 (T‑cell receptor complex), redirecting endogenous T cells to deplete B cells.
- Mechanism: The program is designed to reset B cells by using mRNA to direct the endogenous, in vivo production of T‑cell engagers – rather than manufacturing and administering the recombinant protein externally.
- Innovation: The first mRNA‑encoded T‑cell engager to enter clinical evaluation for autoimmune diseases, according to Abogen.
- Differentiation: Offers a highly differentiated mechanism for B‑cell depletion with potential distinct advantages over traditional recombinant T‑cell engagers, aligned with Abogen’s goal of delivering differentiated, accessible and scalable therapies for B‑cell‑mediated disorders.
Platform & Pipeline Context
- Clinical Status: ABO2203 is in clinical evaluation; specific trial phase, design and data were not disclosed in the announcement.
- Proprietary Platform: An AI‑ and automation‑driven mRNA and LNP platform with end‑to‑end capabilities spanning mRNA design, formulation development and large‑scale GMP manufacturing.
- Pipeline Breadth: A diversified portfolio across oncology, autoimmune diseases and prophylactic vaccines.
- Other Lead Asset: ABO1108, a lyophilized mRNA shingles vaccine, currently in Phase 3 clinical trials in China.
Market Impact & Outlook
- Deal Economics: A USD 575 million upfront payment plus up to approximately USD 7.2 billion in potential milestone payments – subject to agreed development, regulatory and commercial milestones – and potential royalties, representing a substantial validation of an early‑clinical mRNA asset from a Chinese biotechnology group.
- Autoimmune Landscape: Fiona Marshall, President of Biomedical Research at Novartis, noted that achieving effective and durable immune reset remains an important goal across a number of autoimmune diseases, and that mRNA‑encoded T‑cell engagers could complement existing therapeutic modalities by enabling in vivo production of these molecules.
- Strategic Validation: Bo Ying, Chief Executive Officer of Abogen, said the agreement marks an important milestone underscoring the broad potential of the company’s RNA platform to expand beyond prophylactic vaccines, and will help accelerate ABO2203 and unlock new therapeutic targets.
- Platform Optionality: The exclusive options over next‑generation assets give Novartis a structured path to broaden the collaboration, while providing Abogen with multiple potential value inflection points tied to option exercises.
- Next Steps: The transaction remains subject to customary closing conditions, including required regulatory clearances.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding the proposed licensing and option agreement between Abogen Biosciences and Novartis, including the potential benefits of the transaction, the development of ABO2203 and other programs, the exercise of options, milestone payments, regulatory progress and future clinical outcomes. Actual results may differ materially from those expressed or implied due to risks and uncertainties inherent in drug discovery, clinical development and regulatory review, as well as the satisfaction of closing conditions.-Fineline Info & Tech
